Literature DB >> 10444248

Systemic sclerosis: an autoantibody mosaic.

C C Bunn, C M Black.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10444248      PMCID： PMC1905344          DOI： 10.1046/j.1365-2249.1999.00990.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  23 in total

Review 1.  Autoantibodies in polymyositis.

Authors:  I N Targoff
Journal:  Rheum Dis Clin North Am       Date:  1992-05       Impact factor: 2.670

2.  Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

Authors:  C C Bunn; C P Denton; X Shi-Wen; C Knight; C M Black
Journal:  Br J Rheumatol       Date:  1998-01

3.  HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients.

Authors:  G C Fanning; K I Welsh; C Bunn; R Du Bois; C M Black
Journal:  Br J Rheumatol       Date:  1998-02

4.  Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis.

Authors:  F C Arnett; J D Reveille; R Goldstein; K M Pollard; K Leaird; E A Smith; E C Leroy; M J Fritzler
Journal:  Arthritis Rheum       Date:  1996-07

5.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Authors:  G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes.

Authors:  M Kuwana; Y Okano; J Kaburaki; T A Medsger; T M Wright
Journal:  Arthritis Rheum       Date:  1999-02

7.  Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera.

Authors:  M Satoh; A K Ajmani; T Ogasawara; J J Langdon; M Hirakata; J Wang; W H Reeves
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Autoantibody reactive with RNA polymerase III in systemic sclerosis.

Authors:  Y Okano; V D Steen; T A Medsger
Journal:  Ann Intern Med       Date:  1993-11-15       Impact factor: 25.391

9.  Autoantibody to RNA polymerase I in scleroderma sera.

Authors:  G Reimer; K M Rose; U Scheer; E M Tan
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

10.  Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus.

Authors:  P J Utz; M Hottelet; P H Schur; P Anderson
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307
View more
  19 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 2.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

3.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 4.  Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.

Authors:  Sreemanti Basu; Bonnie N Dittel
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

5.  IMPACT OF AGE AND AUTOANTIBODY STATUS ON THE GENE EXPRESSION OF SCLERODERMA FIBROBLASTS IN RESPONSE TO SILICA STIMULATION.

Authors:  Y Yang; P Wei; X J Guo; D Zhou; W Z Zhang; S Assassi; X D Zhou
Journal:  Eur J Inflamm       Date:  2013-09       Impact factor: 0.466

6.  B cell block: is rituximab a new possible treatment for systemic sclerosis?

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2010-11-20       Impact factor: 5.782

7.  Clinical and serological features of systemic sclerosis in a Chinese cohort.

Authors:  Jiucun Wang; Shervin Assassi; Gang Guo; Wenzhen Tu; Wenyu Wu; Li Yang; Rong Xiao; Yongqiang Zhao; Haiyan Chu; Jie Liu; Yanyun Ma; Sarah J Kim; Li Jin; Maureen D Mayes; Hejian Zou; Xiaodong Zhou
Journal:  Clin Rheumatol       Date:  2012-12-28       Impact factor: 2.980

8.  A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.

Authors:  Winston S J Chang; Joanna Schollum; Douglas H N White; Kamal K Solanki
Journal:  Clin Rheumatol       Date:  2015-05-29       Impact factor: 2.980

9.  HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans.

Authors:  Xiaodong Zhou; Jong Eun Lee; Frank C Arnett; Momiao Xiong; Min Young Park; Yeon Kyeong Yoo; Eun Soon Shin; John D Reveille; Maureen D Mayes; Jin Hyun Kim; Ran Song; Ji Yong Choi; Ji Ah Park; Yun Jong Lee; Eun Young Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Arthritis Rheum       Date:  2009-12

Review 10.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.